Maybe I'm just missing something, but on a quick look, I find it a bit strange that since issues with thrombocyte (platelet) counts in adenovirus-vectored therapeutics have (1) been known for about two decades and (2) the ChAd3 (Ebola vaccine) trials have have looked at these over and over and the papers had something to say on the topic, albeit reassuring things like "No clinically meaningful thrombocytopenia was reported" or "None of the prolongations [of partial-thromboplastin time] were associated with symptoms or clinical features of coagulopathy"... the ChAdOx1 (Covid-19 vaccine) trials don't seem to mention such issues at all, at least in the two Lancet papers I found (Aug 15; Dec 8).
After all the brouhaha with temporary suspension of the AZ vaccine (turned permanent in some countries like Denmark or Norway), there's now a draft paper based on a survey in Norway that suggests there's even more besides the severe cases namely that
The hypothesis is that milder symptoms indicating altered thrombocyte function may affect a larger proportion of vaccinated individuals than the recently reported severe cases with thrombosis and thrombocytopenia. [...]
More than 80 000 cohort participants responding to electronic questionnaires about covid-19 vaccination and potential side effects during weeks 11-13, 2021. [...]
Four of the 3416 subjects (0.2%) who were vaccinated with a single dose of mRNA vaccine reported skin bleeding as a side effect, as opposed to 163 of 5132 subjects (3.2%) vaccinated with a single dose of the adenovirus-vectored vaccine, OR (odds ratio)=16.0 (95% confidence interval (CI) 7.5-34.1). Corresponding ORs for nose and gingival bleeding were 8.0 (4.0-15.8) and 9.3 (4.3-20.0), respectively.
This was a survey conducted on March 17 after the suspension of the AZ vaccine in Norway (on March 11), so it's possible that the respondents were influenced by the news etc. But 3.2% is a high enough percentage of side effects that some of it should/would have been spotted in clinical trials, had these particular kinds of events been measured back then.
So, my question is: were bleeding events or thrombocyte counts measured at all in any ChAdOx1 clinical trials?